Drug Trial Radar · NCT03711032
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,397
Planned (sponsor's estimate)
Start
Dec 24, 2018
Primary completion
Jul 31, 2028
Study completion Nov 20, 2034
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. The goals of this study are to learn: 1. If more people who receive pembrolizumab with Bacillus Calmette-Guerin (BCG) have no signs of cancer in their body and live longer without the cancer growing, spreading, or coming back compared to people who receive BCG alone. 2. About the safety and how well people tolerate BCG alone or in combination with pembrolizumab.
Conditions
- High-risk Non-muscle Invasive Bladder Cancer
Interventions
PembrolizumabBiological
Pembrolizumab IV infusion of 200 mg Q3W for BCG Post-Induction Cohort (Cohort A), or IV infusion of 400 mg Q6W for BCG Naïve Cohort (Cohort B), according to randomization
BCGBiological
BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Response Rate (CRR) by Blinded Independent Central Review (BICR) (Cohort A)Time frame: Up to ~3.5 years
- Event-Free Survival (EFS) (Cohort B)Time frame: Up to ~5 years
Locations
209 sites in 30 countries. Site status is shown where the registry gives one.
Alaska Urological Institute dba Alaska Clinical Research Center ( Site 1083)
Anchorage, Alaska
Mayo Clinic in Arizona - Phoenix ( Site 1094)
Phoenix, Arizona
Del Sol Research Management, LLC ( Site 1096)
Tucson, Arizona
UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 1052)
Los Angeles, California
University of California Irvine Medical Center ( Site 1061)
Orange, California
Genesis Research LLC ( Site 1065)
Torrance, California
Colorado Clinical Research ( Site 1100)
Lakewood, Colorado
Urological Research Network ( Site 1106)
Hialeah, Florida
Mayo Clinic in Florida-Urology ( Site 1097)
Jacksonville, Florida
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1056)
Miami, Florida
Woodlands Medical Specialists, PA ( Site 8002)
Pensacola, Florida
Emory School of Medicine ( Site 1076)
Atlanta, Georgia
Advanced Urology ( Site 1092)
Roswell, Georgia
Northwestern Memorial Hospital ( Site 1101)
Chicago, Illinois
Wichita Urology Group ( Site 1086)
Wichita, Kansas
Ochsner LSU Health Shreveport - Regional Urology ( Site 1099)
Shreveport, Louisiana
Henry Ford Hospital ( Site 1062)
Detroit, Michigan
Michigan Institute of Urology ( Site 1077)
Troy, Michigan
Coastal Urology Associates ( Site 1055)
Brick, New Jersey
Morristown Medical Center ( Site 1090)
Morristown, New Jersey
Rutgers Cancer Institute of New Jersey ( Site 1059)
New Brunswick, New Jersey
St. Peter's Hospital Cancer Care Center ( Site 1087)
Albany, New York
R.J. Zuckerberg Cancer Center ( Site 1080)
Lake Success, New York
Veterans Affairs New York Harbor Healthcare System-PCF COE ( Site 1112)
New York, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 1074)
New York, New York
Associated Medical Professionals of NY ( Site 1078)
Syracuse, New York
TriState Urologic Services PSC Inc. dba The Urology Group ( Site 1091)
Cincinnati, Ohio
University Hospitals Cleveland Medical Center ( Site 1066)
Cleveland, Ohio
Ohio State University Arthur G James Cancer Hospital & Richard J Solove Research Institute ( Site 1067)
Columbus, Ohio
OHSU Knight Cancer Institute ( Site 1075)
Portland, Oregon
Oregon Urology Institute ( Site 1098)
Springfield, Oregon
MidLantic Urology ( Site 1071)
Bala-Cynwyd, Pennsylvania
Lancaster Urology ( Site 1079)
Lancaster, Pennsylvania
University of Pennsylvania ( Site 1088)
Philadelphia, Pennsylvania
Carolina Urologic Research Center ( Site 1085)
Myrtle Beach, South Carolina
Urology Associates [Nashville, TN] ( Site 1072)
Nashville, Tennessee
Urology Clinics of North Texas, PLLC ( Site 1064)
Dallas, Texas
University Of Texas Southwestern Medical Center ( Site 1053)
Dallas, Texas
Texas Oncology-Fort Worth Cancer Center ( Site 8003)
Fort Worth, Texas
Houston Metro Urology ( Site 1111)
Houston, Texas
Showing 40 of 209 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.